The effect of overactive bladder treatment with anticholinergics on female sexual function in women: a prospective observational study
- 45 Downloads
The aim of the study was to determine the effect of anticholinergics used for overactive bladder treatment on the sexual function of women.
Between January 2016 and August 2018, over 18 years old, 216 sexual active women with OAB and 165 healthy women as control group were prospectively enrolled in the study. Five different anticholinergics were used for the treatment. Female Sexual Function Index (FSFI), eight-item overactive bladder awareness tool (OAB-V8), and Beck Depression Inventory form were completed before and after 3 months. Baseline and post-treatment scores were compared with a control group of age-matched healthy women.
Patients with OAB reported at baseline significantly worse sexual function in all FSFI domains compared to healthy control group (21.47 ± 3.22 vs. 26.79 ± 5.56, p < 0.01). Three months after treatment, over 85% of participants reported clinically relevant improvements in sexual function, with statistically significant changes in mean FSFI scores.
Treatment of OAB with anticholinergics can improve sexual function of sexual active women with OAB. Patients may be informed about this potential benefit of anticholinergic treatment, to improve their sexual function.
KeywordsAnticholinergic Female sexual functions Overactive bladder
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, Monga A, Petri E, Rizk DE, Sand PK, Schaer GN, International Urogynecological Association, International Continence Society (2010) An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 29(1):4–20. https://doi.org/10.1002/nau.20798 Google Scholar
- 3.Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I (2008) The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int 101(11):1388–1395. https://doi.org/10.1111/j.1464-410X.2008.07601.x CrossRefGoogle Scholar
- 12.Gormley EA, Lightner DJ, Faraday M, Vasavada SP, American Urological Association, Society of Urodynamics FPM (2015) Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol 193(5):1572–1580. https://doi.org/10.1016/j.juro.2015.01.087 CrossRefGoogle Scholar
- 17.Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, Van Kerrebroeck P, Victor A, Wein A, Standardisation Sub-Committee of the International Continence S (2003) The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 61(1):37–49CrossRefGoogle Scholar
- 19.Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, Ferguson D, D’Agostino R Jr (2000) The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 26(2):191–208. https://doi.org/10.1080/009262300278597 CrossRefGoogle Scholar
- 24.Rogers R, Bachmann G, Jumadilova Z, Sun F, Morrow JD, Guan Z, Bavendam T (2008) Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women. Int Urogynecol J Pelvic Floor Dysfunct 19(11):1551–1557. https://doi.org/10.1007/s00192-008-0688-6 CrossRefGoogle Scholar
- 25.Sand PK, Goldberg RP, Dmochowski RR, McIlwain M, Dahl NV (2006) The impact of the overactive bladder syndrome on sexual function: a preliminary report from the multicenter assessment of transdermal therapy in overactive bladder with oxybutynin trial. Am J Obstet Gynecol 195(6):1730–1735. https://doi.org/10.1016/j.ajog.2006.08.013 CrossRefGoogle Scholar